From Bench to bedside and back again-emerging opportunities

Christopher Buckley; Barry Bresnihan

doi:10.1016/j.berh.2006.07.001

From Bench to bedside and back again-emerging opportunities

Christopher Buckley, Barry Bresnihan

Inflammation and Ageing

Research output: Contribution to journal › Article › peer-review

10 Downloads (Pure)

Abstract

We believe that an exciting new era of innovative therapeutic advancement has already begun. Patients with severe chronic rheumatic diseases can realistically entertain the expectation of substantial symptomatic improvement, or even of cure. The excitement of both scientists and clinicians is highlighted in this edition of Best Practice and Research Clinical Rheumatology. The proof of principle that targeting cytokines, such as tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β), with biological reagents may lead to spectacular biological outcomes has led us to believe that some diseases might even be cured.

Original language	English
Pages (from-to)	827-828
Number of pages	2
Journal	Best Practice and Research: Clinical Rheumatology
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/j.berh.2006.07.001
Publication status	Published - Oct 2006

Access to Document

10.1016/j.berh.2006.07.001Licence: None: All rights reserved

Cite this

@article{44c65b68aeb64c2ca937cea46323807c,

title = "From Bench to bedside and back again-emerging opportunities",

abstract = "We believe that an exciting new era of innovative therapeutic advancement has already begun. Patients with severe chronic rheumatic diseases can realistically entertain the expectation of substantial symptomatic improvement, or even of cure. The excitement of both scientists and clinicians is highlighted in this edition of Best Practice and Research Clinical Rheumatology. The proof of principle that targeting cytokines, such as tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β), with biological reagents may lead to spectacular biological outcomes has led us to believe that some diseases might even be cured.",

author = "Christopher Buckley and Barry Bresnihan",

year = "2006",

month = oct,

doi = "10.1016/j.berh.2006.07.001",

language = "English",

volume = "20",

pages = "827--828",

journal = "Best Practice and Research: Clinical Rheumatology",

issn = "1521-6942",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - From Bench to bedside and back again-emerging opportunities

AU - Buckley, Christopher

AU - Bresnihan, Barry

PY - 2006/10

Y1 - 2006/10

N2 - We believe that an exciting new era of innovative therapeutic advancement has already begun. Patients with severe chronic rheumatic diseases can realistically entertain the expectation of substantial symptomatic improvement, or even of cure. The excitement of both scientists and clinicians is highlighted in this edition of Best Practice and Research Clinical Rheumatology. The proof of principle that targeting cytokines, such as tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β), with biological reagents may lead to spectacular biological outcomes has led us to believe that some diseases might even be cured.

AB - We believe that an exciting new era of innovative therapeutic advancement has already begun. Patients with severe chronic rheumatic diseases can realistically entertain the expectation of substantial symptomatic improvement, or even of cure. The excitement of both scientists and clinicians is highlighted in this edition of Best Practice and Research Clinical Rheumatology. The proof of principle that targeting cytokines, such as tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β), with biological reagents may lead to spectacular biological outcomes has led us to believe that some diseases might even be cured.

U2 - 10.1016/j.berh.2006.07.001

DO - 10.1016/j.berh.2006.07.001

M3 - Article

SN - 1521-6942

VL - 20

SP - 827

EP - 828

JO - Best Practice and Research: Clinical Rheumatology

JF - Best Practice and Research: Clinical Rheumatology

IS - 5

ER -

From Bench to bedside and back again-emerging opportunities

Abstract

Access to Document

Fingerprint

Cite this